CNAHealth
GSK to nearly double cancer medicines in trials next year
GSK plans to nearly double the number of cancer medicines in clinical trials next year, expanding its oncology research pipeline. The brief announcement gives no further information about the medicines, their trial stages, or when new trials might begin.
This card is an AI-assisted summary of reporting published by CNA. Read the original report before relying on it for medical, legal, financial, safety, or emergency decisions.